How is it that some covid-19 patients are affected much worse than others? Can we predict beforehand which of them will develop critical symptoms. A diverse consortium of universities, academic hospitals and industrial partners is looking for the answers to these questions.
Pepscope, a biotechnology company with research laboratories at Utrecht ľ¹Ï¸£ÀûÓ°ÊÓ, got 4.3-million-euro funding in collaboration with the Altelaar lab
